Preclinical Evaluation of Invariant Natural Killer T Cells in the 5T33 Multiple Myeloma Model

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Nur, Haneen ^a,b   Fostier, Karel ^c   Aspeslagh, Sandrine ^d   Renmans, Wim ^c   Bertrand, Elisabeth ^e   Leleu, Xavier ^e   Favreau, Mérédis ^a,d   Breckpot, Karine ^a   Schots, Rik ^c   de Waele, Marc ^c   van Valckenborgh, Els ^a   de Bruyne, Elke ^a   Facon, Thierry ^e   Elewaut, Dirk ^d   Vanderkerken, Karin ^a   Menu, Eline ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b HEBRON UNIVERSITY   (Palestine)

^c UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^d GHENT UNIVERSITY   (Belgium)

^e LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD1D ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 4; NATURAL KILLER CELL RECEPTOR; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; CELL SELECTION; CELL SURVIVAL; CLINICAL EVALUATION; CONTROLLED STUDY; DENDRITIC CELL; DISEASE COURSE; DISEASE MODEL; ENZYME INDUCTION; ENZYME RELEASE; HUMAN; HUMAN CELL; MOUSE; MULTIPLE MYELOMA; NATURAL KILLER T CELL; NONHUMAN; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD1D; DISEASE MODELS, ANIMAL; GALACTOSYLCERAMIDES; HUMANS; INTERFERON-GAMMA; LYMPHOCYTE COUNT; MICE; MULTIPLE MYELOMA; NATURAL KILLER T-CELLS;

MURINAE; MUS;

EID: 84878523797     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065075     Document Type: Article

References (41)

1. Neparidze N, Dhodapkar MV, (2009) Harnessing CD1d-restricted T cells toward antitumor immunity in humans. Ann N Y Acad Sci 1174: 61-67.
2. Taniguchi M, Seino K, Nakayama T, (2003) The NKT cell system: bridging innate and acquired immunity. Nat Immunol 4: 1164-1165.
3. Wu L, Van Kaer L, (2009) Natural killer T cells and autoimmune disease. Curr Mol Med 9: 4-14.
4. Bontkes HJ, Moreno M, Hangalapura B, Lindenberg JJ, de Groot J, et al. (2010) Attenuation of invariant natural killer T-cell anergy induction through intradermal delivery of alpha-galactosylceramide. Clin Immunol 136: 364-374.
5. Wu L, Gabriel CL, Parekh VV, Van Kaer L, (2009) Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities. Tissue Antigens 73: 535-545.
6. Morita M, Motoki K, Akimoto K, Natori T, Sakai T, et al. (1995) Structure-activity relationship of alpha-galactosylceramides against B16-bearing mice. J Med Chem 38: 2176-2187.
7. Kobayashi E, Motoki K, Uchida T, Fukushima H, Koezuka Y, (1995) KRN7000, a novel immunomodulator, and its antitumor activities. Oncol Res 7: 529-534.
8. Chang DH, Osman K, Connolly J, Kukreja A, Krasovsky J, et al. (2005) Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med 201: 1503-1517.
9. Tamura Y, Teng A, Nozawa R, Takamoto-Matsui Y, Ishii Y, (2008) Characterization of the immature dendritic cells and cytotoxic cells both expanded after activation of invariant NKT cells with alpha-galactosylceramide in vivo. Biochem Biophys Res Commun 369: 485-492.
10. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, et al. (1997) CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278: 1626-1629.
11. Cerundolo V, Silk JD, Masri SH, Salio M, (2009) Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol 9: 28-38.
12. Song W, van der Vliet HJ, Tai YT, Prabhala R, Wang R, et al. (2008) Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. Clin Cancer Res 14: 6955-6962.
13. Akutsu Y, Nakayama T, Harada M, Kawano T, Motohashi S, et al. (2002) Expansion of lung V alpha 14 NKT cells by administration of alpha-galactosylceramide-pulsed dendritic cells. Jpn J Cancer Res 93: 397-403.
14. Fujii S, Shimizu K, Kronenberg M, Steinman RM, (2002) Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol 3: 867-874.
15. Terabe M, Berzofsky JA, (2008) The role of NKT cells in tumor immunity. Adv Cancer Res 101: 277-348.
16. Dhodapkar MV, Geller MD, Chang DH, Shimizu K, Fujii S, et al. (2003) A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med 197: 1667-1676.
17. Tahir SM, Cheng O, Shaulov A, Koezuka Y, Bubley GJ, et al. (2001) Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J Immunol 167: 4046-4050.
18. Yanagisawa K, Seino K, Ishikawa Y, Nozue M, Todoroki T, et al. (2002) Impaired proliferative response of V alpha 24 NKT cells from cancer patients against alpha-galactosylceramide. J Immunol 168: 6494-6499.
19. Vanderkerken K, Asosingh K, Croucher P, Van Camp B, (2003) Multiple myeloma biology: lessons from the 5TMM models. Immunol Rev 194: 196-206.
20. Radl J, De Glopper ED, Schuit HR, Zurcher C, (1979) Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice. J Immunol 122: 609-613.
21. Vanderkerken K, Asosingh K, Willems A, De Raeve H, Couck P, et al. (2005) The 5T2MM murine model of multiple myeloma: maintenance and analysis. Methods Mol Med 113: 191-205.
22. Vanderkerken K, De Raeve H, Goes E, Van Meirvenne S, Radl J, et al. (1997) Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. Br J Cancer 76: 451-460.
23. Fang X, Du P, Liu Y, Tang J, (2010) Efficient isolation of mouse liver NKT cells by perfusion. PLoS One 5: e10288.
24. Watarai H, Nakagawa R, Omori-Miyake M, Dashtsoodol N, Taniguchi M, (2008) Methods for detection, isolation and culture of mouse and human invariant NKT cells. Nat Protoc 3: 70-78.
25. Breckpot K, Dullaers M, Bonehill A, van Meirvenne S, Heirman C, et al. (2003) Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. J Gene Med 5: 654-667.
26. Spanoudakis E, Hu M, Naresh K, Terpos E, Melo V, et al. (2009) Regulation of multiple myeloma survival and progression by CD1d. Blood 113: 2498-2507.
27. Chang YJ, Huang JR, Tsai YC, Hung JT, Wu D, et al. (2007) Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids. Proc Natl Acad Sci U S A 104: 10299-10304.
28. Mattarollo SR, West AC, Steegh K, Duret H, Paget C, et al. (2012) NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma. Blood 120: 3019-3029.
29. van der Vliet HJ, Wang R, Yue SC, Koon HB, Balk SP, et al. (2008) Circulating myeloid dendritic cells of advanced cancer patients result in reduced activation and a biased cytokine profile in invariant NKT cells. J Immunol 180: 7287-7293.
30. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM, (2003) Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 198: 267-279.
31. Fujii S, Liu K, Smith C, Bonito AJ, Steinman RM, (2004) The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med 199: 1607-1618.
32. Iyoda T, Ushida M, Kimura Y, Minamino K, Hayuka A, et al. (2010) Invariant NKT cell anergy is induced by a strong TCR-mediated signal plus co-stimulation. Int Immunol 22: 905-913.
33. Broxmeyer HE, Christopherson K, Hangoc G, Cooper S, Mantel C, et al. (2012) CD1d expression on and regulation of murine hematopoietic stem and progenitor cells. Blood 119: 5731-5741.
34. Fujii S, Shimizu K, Hemmi H, Steinman RM, (2007) Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity. Immunol Rev 220: 183-198.
35. Pilones KA, Aryankalayil J, Demaria S, (2012) Invariant NKT cells as novel targets for immunotherapy in solid tumors. Clin Dev Immunol 2012: 720803.
36. Miyamoto K, Miyake S, Yamamura T, (2001) A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 413: 531-534.
37. Schmieg J, Yang G, Franck RW, Tsuji M, (2003) Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-Galactosylceramide. J Exp Med 198: 1631-1641.
38. Fujii S, Shimizu K, Hemmi H, Fukui M, Bonito AJ, et al. (2006) Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice. Proc Natl Acad Sci U S A 103: 11252-11257.
39. Aspeslagh S, Li Y, Yu ED, Pauwels N, Trappeniers M, et al. (2011) Galactose-modified iNKT cell agonists stabilized by an induced fit of CD1d prevent tumour metastasis. EMBO J 30: 2294-2305.
40. Tyznik AJ, Farber E, Girardi E, Birkholz A, Li Y, et al. (2011) Glycolipids that elicit IFN-gamma-biased responses from natural killer T cells. Chem Biol 18: 1620-1630.
41. Richter J, Neparidze N, Zhang L, Nair S, Monesmith T,et al. (2012) Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma. Blood.